Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab + paclitaxel + carboplatin + bevacizumab in ovarian and related cancers
CTR20170612Phase 3Completed
- Sponsor
- Roche
- Start
- Oct 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of atezolizumab in Ovarian Epithelial Adenocarcinoma, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), Extrauterine Müllerian Carcinoma (EMC), sponsored by Roche. Started Oct 2017; status: completed.
02
Drugs
atezolizumab
03
Conditions
Ovarian Epithelial Adenocarcinomafallopian tube cancer (PFTC)primary peritoneal cancer (PPC)Extrauterine Müllerian Carcinoma (EMC)
Beyond the preview
Go deeper on CTR20170612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20170612.